Evidence map›Paper›PMID 40630853›Full record

ArticleCurrent treatment options in allergy2025

Innovations and Emerging Therapies in Atopic Dermatitis Part 2.

Robyn Okereke, Eric Simpson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current treatment options in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robyn OkerekeDepartment of Dermatology, Oregon Health and Sciences University, 3303 S Bond Ave Building 1, 16th Floor, Portland, OR 97239, USA.
Eric SimpsonDepartment of Dermatology, Oregon Health and Sciences University, 3303 S Bond Ave Building 1, 16th Floor, Portland, OR 97239, USA.

Funding

Experimental and Computational Analysis of the Human Epidemiology and Response to SARS-CoV-2 (HEROS) CohortUM1AI151958 · NIAID · NATIONAL JEWISH HEALTH · PI Donald YM Leung · 2020 to 2026
$38.3M
NIAID NIH HHS UM1 AI151958
6 · The paper itself

Abstract

Purpose of Review: The purpose of this review is to discuss the novel aspects of topical therapies used for the treatment of AD. We also discuss the lapses observed when comparing topical therapies. After the innovations regarding systemic therapies in AD were highlighted in a first review (part 1), this second component (part 2) will perceive the advances in topical therapies for AD. Recent Findings: Recent history has realized a prompt evolution in the options for topical therapy in AD. Novel, molecularly targeted topical therapies appear to address the drawbacks of traditional topical medicines. Summary: The transformation towards targeted AD therapies is associated with increased efficacy and safety profiles, as well as patient compliance. We also evaluate available real-world and long-term data. Future studies should focus on optimizing topical therapies by increasing the duration of available long-term data.

Indexed as

Atopic DermatitisEmerging therapyInnovationsTargeted therapyTopicals eczemaTopical therapy

Identifiers

PMID40630853
PMCPMC12233182

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.